Is Jazz Pharmaceuticals plc (JAZZ) a Buy, Sell, or Hold?
Jazz Pharmaceuticals plc
NASDAQ:JAZZ
$238.05 USD
$1.08 (0.46%)
- Volume
- 747.01K
- Average Volume
- 933.64K
- Market Capitalization
- $14.95B
- P/E Ratio
- 580.61
- Dividend Yield
- 0.00%
- Price Target
- $257.00
- Year High
- $250.49
- Year Low
- $105.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.04
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Renee D. Gala |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | JAZZ |
| CUSIP | G50871105 |
| CIK | 0001232524 |
| Web | https://www.jazzpharma.com |
| Phone | 353 1 634 7800 |
| Currency | USD |
| Employees | 2890 |
| Country | IE |
Liquidity
| Debt-to-Equity Ratio | 1.20 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.04 |
| Quick Ratio | 1.85 |
| Cash Ratio | 0.82 |
Sales & Book Value
| Annual Sales | $4.27B |
| Price / Sales | 3.37 |
| Cash Flow | 20.12 |
| Price / Cash Flow | 12.01 |
| Price / Book | 3.25 |
Price Target and Rating
| Average Stock Price Forecast | $257.00 |
| High Stock Price Forecast | $307.00 |
| Low Stock Price Forecast | $229.00 |
| Forecast Upside/Downside | -7.37% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 48 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-5.84 |
| Trailing P/E Ratio | 580.61 |
| PEG Ratio | -1.96 |
| P/E Growth | -1.96 |
| Net Income | $-356.15M |
| Net Margin | 0.66% |
| Pretax Margin | -4.93% |
| Return on Equity | 0.71% |
| Return on Assets | 0.25% |
Financials Score
| AltmanZ Score | 1.94 |
| Piotroski Score | 6.00 |
| Working Capital | 2.34B |
| Total Assets | 11.86B |
| Ebit | -14.39M |
| Market Cap | 14.89B |
| Total Liabilities | 7.33B |
Poll Results
About Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harb ... oring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
iShares Russell 2000 Value vs. Morningstar Small Cap: Which ETF Suits Your Portfolio Best?
2026-07-07 07:40:01
IWN delivered a 37.4% one-year return but carries higher fees, while ISCV offers a 0.06% expense ratio and stronger dividend yield of 1.9%.
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
2026-07-06 10:40:32
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Jazz Pharmaceuticals (JAZZ) Price Forecast: Will Breakout Confirm Higher Highs?
2026-07-02 17:03:00
Jazz Pharmaceuticals is testing a bull flag breakout following a long-term base advance, with confirmation needed above key swing resistance to validate continuation toward new highs.
Jazz Pharmaceuticals (JAZZ) is a Top-Ranked Momentum Stock: Should You Buy?
2026-06-30 10:52:17
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
2026-06-23 14:40:00
Zepzelca's failed trial doesn't derail Jazz's growth strategy. First-line adoption is becoming Zepzelca's biggest opportunity.
JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapies
2026-06-18 11:31:04
Jazz Pharmaceuticals teams up with AbCellera to discover and develop T-cell-engaging antibodies for GI cancers and other solid tumors.
Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration
2026-06-17 12:54:55
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) announced on Wednesday a collaboration with AbCellera Biologics Inc. (NASDAQ:ABCL) to discover next-generation T-cell-engaging multispecific antibodies.
Jazz Pharma, AbCellera ink antibody deal worth up to $876 million
2026-06-17 07:43:56
Jazz Pharmaceuticals has signed a research collaboration and licensing agreement with Canada's AbCellera to develop T-cell engaging multispecific antibodies for cancer, the companies said on Wednesday.
Frequently Asked Questions
-
What is the current Jazz Pharmaceuticals plc (JAZZ) stock price?
-
Jazz Pharmaceuticals plc(NASDAQ:JAZZ) stock price is $238.05 in the last trading session. During the trading session, JAZZ stock reached the peak price of $250.49 while $105 was the lowest point it dropped to. The percentage change in JAZZ stock occurred in the recent session was 0.46% while the dollar amount for the price change in JAZZ stock was $1.08.
-
JAZZ's industry and sector of operation?
-
The NASDAQ listed JAZZ is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of JAZZ?
-
John D. Bluth | Head of Investor Relations
Thomas J. Riga | Senior Vice President & Chief Business Officer
Heidi Manna | Executive Vice President & Chief People Officer
Patricia Carr | Senior Vice President & Chief Accounting Officer
Philip L. Johnson | Executive Vice President & Chief Financial Officer -
How many employees does JAZZ have?
-
Number of JAZZ employees currently stands at 2890. JAZZ operates from Waterloo Exchange, Dublin, DU D04 E5W7, IE.
-
Link for JAZZ official website?
-
Official Website of JAZZ is: https://www.jazzpharma.com
-
How do I contact JAZZ?
-
JAZZ could be contacted at phone #353 1 634 7800 and can also be accessed through its website. JAZZ operates from Waterloo Exchange, Dublin, DU D04 E5W7, IE.
-
How many shares of JAZZ are traded daily?
-
The average number of JAZZ shares traded daily for last 3 months was 933.64K.
-
What is the market cap of JAZZ currently?
-
The market value of JAZZ currently stands at $14.95B with its latest stock price at $238.05